… COVID-19 despite the use of immunosuppressive therapy. Marked adherence of patients
with AIH to protective guidelines during the COVID-19 … compatible with COVID-19 were noted …

… immunosuppressant medications – both for COVID-19-free patients in the community in the
context of the pandemic and for patients with active COVID-19 … immunosuppressive therapy …

… of immunosuppressive drugs … COVID 19 pandemic, relatively few studies on COVID-19 are
completed. Therefore, we also searched for papers reporting the effect of immunosuppressive …

… immunosuppressive therapies in COVID-19 outcomes after SARS-CoV-2 infection. While
immunosuppression … that patients on immunosuppressive therapy before contracting SARS-…

… or stop the severity of symptoms in confirmed COVID-19 patients. Therefore, we …
immunosuppressive drugs for treating gastrointestinal (GI) disorders. After the outbreak of COVID-19 …

… immunosuppressive therapy around COVID-19 vaccination will need to be made prior to the
availability of data on specific COVID-19 … on the effect of antirheumatic therapy on vaccine …

… immunosuppression and thus not deemed high risk. This would bias away from demonstrating
harm with immunosuppression. … of immunosuppression on COVID-19 risk and COVID-19 …

… inflammation therapies. It is still too early to forecast the risk of infection and disease severity
of COVID-19 in patients with RD, especially those who are on immunosuppressive therapies…

… of the effects of immunosuppressive therapy, which may … abounds in the therapeutic tactics
employed in COVID-19. It … of this disease to facilitate therapeutic application and evaluate …

… Several reports have suggested that IS therapy does not increase the prevalence of COVID-19
in patients with IMID. However, these studies had the potential to miss many COVID-19 …